WO2002081621A3 - Vaccin contre le virus de la fievre du nil - Google Patents

Vaccin contre le virus de la fievre du nil Download PDF

Info

Publication number
WO2002081621A3
WO2002081621A3 PCT/FR2002/001200 FR0201200W WO02081621A3 WO 2002081621 A3 WO2002081621 A3 WO 2002081621A3 FR 0201200 W FR0201200 W FR 0201200W WO 02081621 A3 WO02081621 A3 WO 02081621A3
Authority
WO
WIPO (PCT)
Prior art keywords
expression vectors
virus
fever virus
nile fever
vivo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2002/001200
Other languages
English (en)
Other versions
WO2002081621A2 (fr
Inventor
Sheena May Loosmore
Jean-Christophe Franc Audonnet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Animal Health France SAS
Boehringer Ingelheim Animal Health USA Inc
Original Assignee
Merial SAS
Merial Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BRPI0208896A priority Critical patent/BRPI0208896B1/pt
Priority to EP02759818.4A priority patent/EP1377660B1/fr
Priority to ES02759818.4T priority patent/ES2566044T3/es
Priority to AU2002307971A priority patent/AU2002307971B2/en
Priority to PL365210A priority patent/PL207584B1/pl
Priority to EP15162832.8A priority patent/EP2979705B1/fr
Priority to CA2448796A priority patent/CA2448796C/fr
Priority to DK02759818.4T priority patent/DK1377660T3/en
Priority to MXPA03008998A priority patent/MXPA03008998A/es
Application filed by Merial SAS, Merial Inc filed Critical Merial SAS
Priority to HU0401868A priority patent/HU230122B1/hu
Priority to HK04104755.3A priority patent/HK1061868B/xx
Priority to SI200231069A priority patent/SI1377660T1/sl
Priority to IL15820402A priority patent/IL158204A0/xx
Priority to JP2002579985A priority patent/JP4426761B2/ja
Publication of WO2002081621A2 publication Critical patent/WO2002081621A2/fr
Publication of WO2002081621A3 publication Critical patent/WO2002081621A3/fr
Priority to ZA2003/07620A priority patent/ZA200307620B/en
Priority to IL158204A priority patent/IL158204A/en
Priority to US10/679,520 priority patent/US20050031641A1/en
Anticipated expiration legal-status Critical
Priority to US10/714,781 priority patent/US7740863B2/en
Priority to IL185263A priority patent/IL185263A0/en
Priority to US12/758,500 priority patent/US8535682B2/en
Priority to FR16C0014C priority patent/FR16C0014I2/fr
Priority to NL300806C priority patent/NL300806I2/nl
Priority to LTPA2016011C priority patent/LTC1377660I2/lt
Priority to BE2016C021C priority patent/BE2016C021I2/fr
Priority to LU93048C priority patent/LU93048I2/fr
Priority to CY2016018C priority patent/CY2016018I2/el
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24171—Demonstrated in vivo effect
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne des vecteurs d'expression in vivo et in vitro comprenant un polynucléotide codant pour la protéine structurale E du virus de la fièvre du Nil ou virus WN, éventuellement associé à un polynucléotide codant pour la protéine de pré-membrane prM et/ou pour la protéine de membrane M, notamment sous la forme codant pour prM-M-E. Des vaccins vivants incorporent de tels vecteurs d'expression in vivo. Les vecteurs d'expression in vitro sont utilisés pour produire les protéines in vitro qui pourront ensuite être utilisées dans des vaccins de sous-unités. L'invention concerne aussi des vaccins multivalents comprenant un composant de vaccin contre le virus WN et un composant de vaccin contre un autre agent pathogène. L'invention vise en particulier les équins, les canins, les félins, les bovins, les porcins et les oiseaux.
PCT/FR2002/001200 2001-04-06 2002-04-05 Vaccin contre le virus de la fievre du nil Ceased WO2002081621A2 (fr)

Priority Applications (26)

Application Number Priority Date Filing Date Title
JP2002579985A JP4426761B2 (ja) 2001-04-06 2002-04-05 ウエストナイル熱ウイルスに対するワクチン
ES02759818.4T ES2566044T3 (es) 2001-04-06 2002-04-05 Vacuna contra el virus de la fiebre del Nilo
AU2002307971A AU2002307971B2 (en) 2001-04-06 2002-04-05 Vaccine against the nile fever virus
PL365210A PL207584B1 (pl) 2001-04-06 2002-04-05 Szczepionka do ochrony koni, psów, kotów, bydła, świń oraz ptaków przed wirusem zachodniego Nilu (WN)
EP15162832.8A EP2979705B1 (fr) 2001-04-06 2002-04-05 Vaccin contre le virus de la fièvre du nil
CA2448796A CA2448796C (fr) 2001-04-06 2002-04-05 Vaccin contre la fievre du nil
DK02759818.4T DK1377660T3 (en) 2001-04-06 2002-04-05 Vaccine against nilfeb ervirus
MXPA03008998A MXPA03008998A (es) 2001-04-06 2002-04-05 Vacuna contra el virus de la fiebre del nilo.
EP02759818.4A EP1377660B1 (fr) 2001-04-06 2002-04-05 Vaccin contre le virus de la fievre du nil
HU0401868A HU230122B1 (hu) 2001-04-06 2002-04-05 Rekombináns vakcina West Nile vírus ellen
HK04104755.3A HK1061868B (en) 2001-04-06 2002-04-05 Vaccine against the nile fever virus
SI200231069A SI1377660T1 (sl) 2001-04-06 2002-04-05 Cepivo proti virusu Zahodnega Nila
IL15820402A IL158204A0 (en) 2001-04-06 2002-04-05 Vaccine against the nile fever virus
BRPI0208896A BRPI0208896B1 (pt) 2001-04-06 2002-04-05 vacina contra o vírus da febre do nilo
ZA2003/07620A ZA200307620B (en) 2001-04-06 2003-09-30 Vaccine against the nile fever virus
IL158204A IL158204A (en) 2001-04-06 2003-10-01 Vaccine composition for inducing a protective immune response against the west nile virus
US10/679,520 US20050031641A1 (en) 2001-04-06 2003-10-06 Recombinant vaccine against West Nile Virus
US10/714,781 US7740863B2 (en) 2001-04-06 2003-11-17 Recombinant vaccine against West Nile Virus
IL185263A IL185263A0 (en) 2001-04-06 2007-08-14 Vaccine against the nile fever virus
US12/758,500 US8535682B2 (en) 2001-04-06 2010-04-12 Recombinant vaccine against West Nile Virus
FR16C0014C FR16C0014I2 (fr) 2001-04-06 2016-04-19 Vaccin contre le virus de la fievre du nil
NL300806C NL300806I2 (fr) 2001-04-06 2016-04-20
LTPA2016011C LTC1377660I2 (lt) 2001-04-06 2016-04-20 Vakcina nuo Nilo karštligės viruso
BE2016C021C BE2016C021I2 (fr) 2001-04-06 2016-04-26
LU93048C LU93048I2 (fr) 2001-04-06 2016-04-26 Proteq west nile
CY2016018C CY2016018I2 (el) 2001-04-06 2016-05-20 Εμβολιο κατα του ιου του δυτικου νειλου

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR01/04737 2001-04-06
FR0104737A FR2823222B1 (fr) 2001-04-06 2001-04-06 Vaccin contre le virus de la fievre du nil

Related Child Applications (4)

Application Number Title Priority Date Filing Date
EP15162832.8A Previously-Filed-Application EP2979705B1 (fr) 2001-04-06 2002-04-05 Vaccin contre le virus de la fièvre du nil
US10/374,953 Continuation-In-Part US20040037848A1 (en) 2001-04-06 2003-02-26 Recombinant vaccine against West Nile Virus
US10/679,520 Continuation-In-Part US20050031641A1 (en) 2001-04-06 2003-10-06 Recombinant vaccine against West Nile Virus
US10/714,781 Continuation-In-Part US7740863B2 (en) 2001-04-06 2003-11-17 Recombinant vaccine against West Nile Virus

Publications (2)

Publication Number Publication Date
WO2002081621A2 WO2002081621A2 (fr) 2002-10-17
WO2002081621A3 true WO2002081621A3 (fr) 2003-02-20

Family

ID=8862055

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2002/001200 Ceased WO2002081621A2 (fr) 2001-04-06 2002-04-05 Vaccin contre le virus de la fievre du nil

Country Status (21)

Country Link
EP (2) EP2979705B1 (fr)
JP (1) JP4426761B2 (fr)
AU (1) AU2002307971B2 (fr)
BE (1) BE2016C021I2 (fr)
BR (1) BRPI0208896B1 (fr)
CA (1) CA2448796C (fr)
CY (2) CY1117676T1 (fr)
DK (1) DK1377660T3 (fr)
ES (2) ES2767413T3 (fr)
FR (2) FR2823222B1 (fr)
HU (2) HU230122B1 (fr)
IL (3) IL158204A0 (fr)
LT (1) LTC1377660I2 (fr)
LU (1) LU93048I2 (fr)
MX (1) MXPA03008998A (fr)
NL (1) NL300806I2 (fr)
PL (2) PL210306B1 (fr)
RU (1) RU2283138C2 (fr)
SI (1) SI1377660T1 (fr)
WO (1) WO2002081621A2 (fr)
ZA (1) ZA200307620B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12391957B2 (en) 2018-08-17 2025-08-19 Icahn School Of Medicine At Mount Sinai Recombinant Newcastle disease viruses and uses thereof for the prevention of RSV disease or human metapneumovirus disease

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2950109C (fr) 2000-10-27 2019-02-19 John W. Hadden Immunotherapie vaccinale pour patients immunodeprimes
ES2435095T3 (es) 2001-07-27 2013-12-18 Zoetis W Llc Vacuna del Nilo Occidental
AU2003296974A1 (en) * 2002-12-13 2004-07-14 Aventis Pasteur, Inc. Production of alvac on avian embryonic stem cells
US8475808B2 (en) 2003-05-23 2013-07-02 Novartis Vaccines And Diagnostics, Inc. Immunogenic reagents from west nile virus
US7482017B2 (en) 2004-09-09 2009-01-27 Research Development Foundation Flavivirus variants having phenotypic variation and immunogenic compositions thereof
JP5603012B2 (ja) 2005-12-02 2014-10-08 トヘ モウント シナイ スクール オフ メディシネ オフ ニューヨーク ウニベルシトイ 非天然表面タンパク質を提示するキメラウイルス及びその使用
SG193821A1 (en) 2008-08-29 2013-10-30 Boehringer Ingelheim Vetmed West nile virus vaccine
EP2393921B1 (fr) 2009-02-05 2015-07-15 Icahn School of Medicine at Mount Sinai Virus chimériques de la maladie de newcastle et leurs utilisations
KR101793195B1 (ko) 2009-03-27 2017-11-02 아카데미아 시니카 바이러스에 대한 면역을 위한 방법 및 조성물
AU2010248761B2 (en) * 2009-05-15 2016-02-11 Irx Therapeutics, Inc. Vaccine immunotherapy
TWI537385B (zh) 2010-11-04 2016-06-11 中央研究院 產生具簡單醣基化之表面蛋白質之病毒顆粒的方法
RU2506093C1 (ru) * 2012-12-06 2014-02-10 Государственное научное учреждение Якутский научно-исследовательский институт сельского хозяйства Российской академии сельскохозяйственных наук Способ специфической профилактики ринопневмонии, сальмонеллезного аборта и мыта лошадей ассоциированной вакциной в условиях табунного содержания
PE20151921A1 (es) 2013-03-14 2015-12-26 Icahn School Med Mount Sinai Virus de la enfermedad de newcastle y usos de los mismos
AU2015222685A1 (en) 2014-02-27 2016-09-08 Viralytics Limited Combination method for treatment of cancer
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
WO2021229270A1 (fr) 2020-05-13 2021-11-18 Laboratorio Avi-Mex, S.A. De C.V. Vaccin recombinant contre la covid-19 à vecteur viral

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000012128A2 (fr) * 1998-08-28 2000-03-09 Hawaii Biotechnology Group, Inc. Vaccin a sous-unite proteique non structurale recombinante contre les infections a flavivirus

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US5110587A (en) 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
EP0173552B1 (fr) 1984-08-24 1991-10-09 The Upjohn Company Composés recombinants d'ADN et l'expression de polypeptides comme le tPA
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4963481A (en) 1985-12-18 1990-10-16 Genetics Institute Inc Promoter system
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB2197321B (en) 1986-09-12 1990-10-03 Genentech Inc Method and vectors for obtaining continuous production of heterologous protein in a eukaryotic host cell line
DE3743138A1 (de) 1987-12-18 1989-09-14 Mayr Christian Gmbh & Co Kg Schleifringlose, elektromagnetische ueberlastkupplung
MY109299A (en) * 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
EP0575491B1 (fr) 1991-03-07 2003-08-13 Virogenetics Corporation Souche de vaccin mise au point par genie genetique
US5843456A (en) 1991-03-07 1998-12-01 Virogenetics Corporation Alvac poxvirus-rabies compositions and combination compositions and uses
US5382425A (en) 1992-01-13 1995-01-17 Syntro Corporation Recombinant swinepox virus
FR2702373B1 (fr) 1993-03-08 1996-06-07 Rhone Merieux Emulsions vaccinales fluides eau-dans-l'huile contenant une huile métabolisable.
EP0668355B1 (fr) 1993-12-20 1999-04-07 Akzo Nobel N.V. Vaccin pour protéger des chevaux contre des infections du virus de l'herpes équin
FR2728795B1 (fr) 1994-12-30 1997-03-21 Rhone Merieux Vaccin vivant recombinant aviaire, utilisant comme vecteur un virus herpes aviaire
FR2728794B1 (fr) 1994-12-30 1997-03-21 Rhone Merieux Vaccin recombinant aviaire a base de virus herpes aviaire, notamment contre la maladie de gumboro
JPH11504631A (ja) 1995-04-25 1999-04-27 バイカル インコーポレイテッド Ｄｎａ／脂質複合体の単一バイアル製剤
AU737243B2 (en) 1996-07-03 2001-08-16 Merial, Inc. Recombinant canine adenovirus (CAV) containing exogenous DNA
FR2751226B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies du cheval
FR2751227B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives
FR2751225B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique aviaire
WO1998016247A1 (fr) 1996-10-11 1998-04-23 The Regents Of The University Of California Conjugues polynucleotide immunostimulateur/molecule immunomodulatrice
ES2345614T3 (es) * 1997-02-28 2010-09-28 Sanofi Pasteur Biologics Co. Vacunas quimericas de flavivirus.
US7227011B2 (en) * 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
US6294176B1 (en) 1998-07-10 2001-09-25 Schering-Plough Veterinary Corp. Recombinant raccoonpox virus and uses thereof as a vaccine in mammalian and avian species
US6645740B1 (en) 1999-06-10 2003-11-11 Merial Limited Nucleic acids encodings equine GM-CSF
BR0011732B1 (pt) 1999-06-10 2014-02-04 Vacinas de dna para animais de companhia e de esporte
FR2796397B1 (fr) 1999-07-16 2006-09-01 Merial Sas Genes de calicivirus felin et vaccins notamment vaccins recombines

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000012128A2 (fr) * 1998-08-28 2000-03-09 Hawaii Biotechnology Group, Inc. Vaccin a sous-unite proteique non structurale recombinante contre les infections a flavivirus

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
OCAZIONEZ JIMENEZ R ET AL: "Recombinant plasmid expressing a truncated dengue-2 virus E protein without co-expression of prM protein induces partial protection in mice", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 19, no. 6, 8 November 2000 (2000-11-08), pages 648 - 654, XP004219903, ISSN: 0264-410X *
WENGLER G ET AL: "AN ANALYSIS OF THE ANTIBODY RESPONSE AGAINST WEST NILE VIRUS E PROTEIN PURIFIED BY SDS-PAGE INDICATES THAT THIS PROTEIN DOES NOT CONTAIN SEQUENTIAL EPITOPES FOR EFFICIENT INDUCTION OF NEUTRALIZING ANTIBODIES", JOURNAL OF GENERAL VIROLOGY, vol. 70, no. 4, 1989, pages 987 - 992, XP001050460, ISSN: 0022-1317 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12391957B2 (en) 2018-08-17 2025-08-19 Icahn School Of Medicine At Mount Sinai Recombinant Newcastle disease viruses and uses thereof for the prevention of RSV disease or human metapneumovirus disease

Also Published As

Publication number Publication date
ES2566044T3 (es) 2016-04-08
SI1377660T1 (sl) 2016-05-31
WO2002081621A2 (fr) 2002-10-17
BE2016C021I2 (fr) 2021-03-23
IL185263A0 (en) 2008-01-06
FR16C0014I1 (fr) 2016-05-27
HUP0401868A3 (en) 2011-06-28
MXPA03008998A (es) 2004-10-15
ES2767413T3 (es) 2020-06-17
FR16C0014I2 (fr) 2016-09-09
FR2823222B1 (fr) 2004-02-06
BRPI0208896B1 (pt) 2016-06-07
HU230122B1 (hu) 2015-08-28
IL158204A0 (en) 2004-05-12
RU2283138C2 (ru) 2006-09-10
BR0208896A (pt) 2004-07-20
CA2448796A1 (fr) 2002-10-17
PL365210A1 (en) 2004-12-27
CY1117676T1 (el) 2016-12-14
IL158204A (en) 2013-03-24
AU2002307971B2 (en) 2008-01-17
EP2979705A1 (fr) 2016-02-03
JP2004531521A (ja) 2004-10-14
PL207584B1 (pl) 2011-01-31
LU93048I2 (fr) 2016-06-27
LTC1377660I2 (lt) 2017-04-25
ZA200307620B (en) 2005-07-27
HK1061868A1 (zh) 2004-10-08
EP1377660A2 (fr) 2004-01-07
CY2016018I1 (el) 2016-12-14
HUP0401868A2 (hu) 2004-12-28
PL210306B1 (pl) 2011-12-30
RU2003132455A (ru) 2005-04-27
NL300806I2 (fr) 2016-06-09
HK1219412A1 (zh) 2017-04-07
DK1377660T3 (en) 2016-03-29
EP1377660B1 (fr) 2016-01-13
FR2823222A1 (fr) 2002-10-11
CY2016018I2 (el) 2016-12-14
EP2979705B1 (fr) 2019-10-23
CA2448796C (fr) 2012-11-20
JP4426761B2 (ja) 2010-03-03
HUS1500047I1 (hu) 2017-03-28

Similar Documents

Publication Publication Date Title
CY1117676T1 (el) Εμβολιο κατα του ιου του δυτικου νειλου
WO2009034315A3 (fr) Vaccin
WO2003059381A3 (fr) Préparations immunogènes et vaccins à base d'arn
SG153874A1 (en) Neutralizing epitope-based growth enhancing vaccine
NO20010922L (no) Fremgangsmåte for DNA vaksinering
NO20016243D0 (no) Anti-alfav-beta3-rekombinante humane antistoffer, nukleinsyrer som koder for de samme og fremgangsmåter foranvendelse
UA110328C2 (en) Recombinant vaccine based on avian paramixoviruses and method for its preparation and administration
GT200200139A (es) Vacuna de mycoplasma bovis y metodos para reducir la neumonia en animales
ES2190908T1 (es) Composicion cosmetica que comprende seroalbumina humana obtenida de animales transgenicos no humanos.
WO2007024947A3 (fr) Vaccins contre la grippe canine
AR047581A1 (es) Vacunas de calicivirus felino
WO2003030656A3 (fr) Procedes et compositions pour favoriser la croissance et l'immunite naturelle chez de jeunes animaux
ATE442857T1 (de) Vakzine zusammensetzung zur impfung von hunden gegen infektiöse atemwegserkrankung bei hunden (cird)
DE60239753D1 (de) Impfstoff gegen infektiöses lachsanämievirus
AR019785A1 (es) Pestivirus no diseminantes
DE602005011041D1 (de) Wachstumshormon-freisetzendes hormon verstärkt die vakzin-induzierte immunantwort
WO2004058816A3 (fr) Corps d'inclusion pour la vaccination orale d'animaux
DE60126490D1 (de) Adjuvanszusammensetzung enthaltend fha oder ein fha-fragment in freier form
WO2004058806A3 (fr) Corps d'inclusion utilises comme antigenes dans la vaccination d'animaux
WO2004073604A3 (fr) Vaccins adn exprimant une toxine adp-ribosyltransferase depourvue d'activite adp-ribosyltransferase
AU2003287061A8 (en) Ferritin light subunit variant-encoding nucleic acids, polypeptides, transgenic animals, antibodies, and methods of use thereof
MXPA01002178A (es) Secuencia de adn que codifica la proteina de membrana, externa especifica y antigena de almonella typh1.
EP1975238A4 (fr) Construction génique, vecteur et vaccin d'adn pour la vaccination d'animaux aquatiques
DK1027895T3 (da) Erysipelothrix rhusiopathiae-antigener og vaccinepræparater
DE60236943D1 (de) Induzierte immunantwort gegen den katzen-immunschwäche-virus

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2003/07620

Country of ref document: ZA

Ref document number: 200307620

Country of ref document: ZA

Ref document number: 2448796

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 158204

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/008998

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2002579985

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002307971

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2002759818

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002759818

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 185263

Country of ref document: IL

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)